# Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

> **NCT03405142** · PHASE2 · COMPLETED · sponsor: **Eben Rosenthal** · enrollment: 3 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Head and Neck Cancer

## Interventions

- **DRUG:** Panitumumab-IRDye800
- **DRUG:** Lymphoseek

## Key facts

- **NCT ID:** NCT03405142
- **Lead sponsor:** Eben Rosenthal
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-01
- **Primary completion:** 2019-12-04
- **Final completion:** 2021-04-27
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2022-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03405142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03405142, "Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03405142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*